Twin Impex Pharmaceutical Export Profile — India (DGFT 2022–2026)

Name: Twin Impex Pharmaceutical Export Portfolio Dataset — 2 Products, $140.5K FOB USD, India (DGFT 2022–2026)
Creator: TransData Nexus

Suresh Sormare

Explore

Twin Impex — Pharmaceutical Exporter Profile (2026) | 2 Products, $140.5K Trade | TransData Nexus

Product Portfolio — Top 2 by Export Value

Twin Impex exports 2 pharmaceutical products across 2 therapeutic categories.

#	Product	Category	Export Value	Shipments	Market Share	Rank
1	Acetylsalicylic	Combination Drugs	$96.1K	17	2.2%	10
2	Niacin	Lipid & Metabolism	$44.4K	7	1.2%	8

Twin Impex exports 2 pharmaceutical products across 2 therapeutic categories with a total export value of $140.5K. The top category is Combination Drugs (68.4% of portfolio), followed by Lipid & Metabolism (31.6%), indicating a concentrated portfolio with the top 5 products accounting for 100.0% of total export value.

Twin Impex — Corporate Profile & Information

Headquarters, ownership, manufacturing facilities, and key leadership

1Corporate Overview

Twin Impex Private Limited, established on August 14, 1997, is a private limited company based in Navi Mumbai, Maharashtra, India. The company was incorporated under the Corporate Identification Number (CIN) U51900MH1997PTC110097. Its registered office is located at E-16, RH-IV, Sector 6, Vashi, Navi Mumbai 400 703, Maharashtra, India.

As of the latest available records, Twin Impex is classified as a non-government company and is unlisted. The authorized capital is ₹100,000, with a paid-up capital of ₹0. The company has been marked as "struck off," indicating that it is no longer active in business operations.

2Manufacturing Facilities

There is no publicly available information regarding the manufacturing facilities of Twin Impex Private Limited. The company's current status as "struck off" suggests that it may not have active manufacturing operations.

3Key Leadership

The latest available records do not provide specific details about the key leadership of Twin Impex Private Limited. Given the company's "struck off" status, it is likely that the leadership team is no longer active or has been dissolved.

TransData Nexus Research · Government registries, company filings, regulatory databasesMar 2026

Where Does Twin Impex Export? — Destination Intelligence

Regulated market presence, emerging market penetration, and geographic strategy

1Regulated Markets

Twin Impex Private Limited has engaged in export activities, with a total export value of $141,000 USD across 24 shipments. The company has exported products to various markets, including Guinea, Senegal, and Angola. The primary products exported are Acetylsalicylic and Niacin, which fall under the therapeutic categories of Combination Drugs and Lipid & Metabolism, respectively. However, the company's current "struck off" status may affect its ability to maintain regulatory approvals and market access in these regions.

2Emerging Markets

Twin Impex Private Limited has engaged in export activities to emerging markets such as Guinea, Senegal, and Angola. The company's export data indicates shipments to these countries, suggesting a presence in these regions. However, the company's current "struck off" status may impact its ability to continue operations in these markets.

3Geographic Strategy

Twin Impex Private Limited's export activities have been concentrated in specific markets, including Guinea, Senegal, and Angola. This focus indicates a strategic approach targeting emerging markets. However, the company's current "struck off" status suggests a lack of diversification in its geographic strategy, potentially exposing it to risks associated with over-reliance on a limited number of markets.

Twin Impex — Manufacturing & Regulatory Profile

FDA status, WHO-GMP certification, EU GMP compliance, and regulatory track record

1FDA Status

There is no publicly available information regarding Twin Impex Private Limited's registration with the U.S. Food and Drug Administration (FDA), approved Abbreviated New Drug Applications (ANDAs), Drug Master File (DMF) filings, or inspection history. Given the company's "struck off" status, it is unlikely that the company holds active FDA approvals or registrations.

2WHO & EU GMP

There is no publicly available information indicating that Twin Impex Private Limited holds World Health Organization (WHO) prequalification or European Union Good Manufacturing Practice (EU GMP) certificates. The company's current "struck off" status suggests that it may not possess these certifications.

3CDSCO & Indian Regulatory

There is no publicly available information regarding Twin Impex Private Limited's manufacturing licenses from the Central Drugs Standard Control Organisation (CDSCO), approvals from state drug controllers, or export No Objection Certificates (NOCs). The company's "struck off" status indicates that it may not hold active regulatory approvals or licenses.

Twin Impex — Competitive Positioning Among Indian Pharma Exporters

Market share comparison, key differentiators, and strategic analysis

1Competitive Landscape

Given the company's "struck off" status, Twin Impex Private Limited is no longer an active competitor in the pharmaceutical export market. Therefore, a competitive analysis is not applicable.

2Key Differentiators

As Twin Impex Private Limited is currently "struck off" and no longer active, it does not possess any key differentiators or competitive advantages in the market.

3Strategic Position

Twin Impex Private Limited's strategic direction, focusing on exporting finished pharmaceutical formulations such as Acetylsalicylic and Niacin, indicates a specialization in specific therapeutic categories. However, the company's current "struck off" status suggests that it is no longer pursuing this strategic direction.

TransData Nexus Research · DGFT export records, industry analysisMar 2026

Buyer Due Diligence Brief — Evaluating Twin Impex as a Supplier

Track record assessment, certifications to verify, and pre-order checks

1Supplier Assessment

As Twin Impex Private Limited is currently "struck off" and no longer active, it is not a viable supplier. Therefore, an assessment of its track record, export volume, consistency, and reliability is not applicable.

2Certifications to Verify

Given the company's "struck off" status, Twin Impex Private Limited is not an active exporter, and therefore, there are no certifications to verify.

3Due Diligence Checklist

As Twin Impex Private Limited is currently "struck off" and no longer active, there are no actionable verification steps, red flags, or recommended pre-order checks applicable to this company.

TransData Nexus Research · FDA, WHO, EMA regulatory databasesMar 2026

Frequently Asked Questions — Twin Impex

How many pharmaceutical products does Twin Impex export from India?

Twin Impex exports 2 pharmaceutical products across 2 therapeutic categories. The top exports are Acetylsalicylic ($96.1K), Niacin ($44.4K). Total export value is $140.5K.

What is Twin Impex's total pharmaceutical export value?

Twin Impex's total pharmaceutical export value is $140.5K, based on 24 verified shipments recorded in Indian Customs (DGFT) data.

What therapeutic categories does Twin Impex cover?

Twin Impex exports across 2 therapeutic categories. The largest are Combination Drugs (68.4%, 1 products), Lipid & Metabolism (31.6%, 1 products).

Get Full Twin Impex Export Intelligence

Access shipment-level details, pricing data, buyer connections, product breakdown, and competitive analysis. TransData Nexus provides verified Indian Customs (DGFT) data trusted by pharmaceutical trade professionals worldwide.

Contact for Data Access Request Live Demo

Official References & Regulatory Resources

Verify manufacturer licensing, GMP certification, and export registration with the agencies above.

Research Methodology & Data Transparency

Suresh Sormare

Verified Author

Pharmaceutical Export-Import Analyst & Trade Intelligence Expert

Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.

linkedin.com/in/sureshsormare

Primary Data Source

All trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.

Data Source & Methodology

Trade data sourced from Indian Customs (DGFT) export shipment records. Values represent FOB export value in USD. Market share calculated relative to total Indian pharmaceutical exports per product category. For current shipment-level data, contact TransData Nexus.

Twin Impex

Twin Impex — Export Portfolio & Destination Treemap

Who is Twin Impex? — Company Overview & Market Position

What Does Twin Impex Export? — Product Portfolio Analysis

Top Products by Export Value

Twin Impex Therapeutic Categories — 2 Specializations